Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $15.33 Analyst target: $45.22 Upside: 194.98%
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.